Hematology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Tisagenlecleucel"

The European Commission ( EC ) has approved Kymriah ( Tisagenlecleucel, formerly CTL019 ). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age wi ...

B2001X is a multicenter global study of Tisagenlecleucel ( Tisa-cel; Kymriah ) to provide access to patients with relapsed / refractory ( r/r ) acute lymphoblastic leukemia ( ALL ) including prior ant ...